About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cdkn2ctm1Yxi
targeted mutation 1, Yue Xiong
MGI:1933762
Summary 8 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi B6.129-Cdkn2ctm1Yxi MGI:3839784
hm2
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi C.129-Cdkn2ctm1Yxi MGI:5517369
hm3
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi involves: 129/Sv * C57BL/6 * DBA/2 MGI:2175774
cx4
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk MGI:5517370
cx5
Brca1tm1Bhk/Brca1tm1Bhk
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk MGI:5517367
cx6
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2 MGI:3639679
cx7
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+
involves: 129/Sv * 129S6/SvEvTac * C57BL/6 MGI:3839785
cx8
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1tm1.1Ctre
involves: 129/Sv * 129S6/SvEvTac * C57BL/6 MGI:3839786


Genotype
MGI:3839784
hm1
Allelic
Composition
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
B6.129-Cdkn2ctm1Yxi
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• lung tumors develop in 20% of mice and are solitary, uniform nodules with clear borders and homogeneous tumor cell type
• bronchioalveolar stem cells are expanded in lung tumors

respiratory system
• lung tumors develop in 20% of mice and are solitary, uniform nodules with clear borders and homogeneous tumor cell type
• bronchioalveolar stem cells are expanded in lung tumors
• bronchioalveolar stem cells are expanded compared to in wild-type mice




Genotype
MGI:5517369
hm2
Allelic
Composition
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
C.129-Cdkn2ctm1Yxi
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mammary glands of virgin females are enriched with luminal stem/progenitors at 6 weeks and 9 months of age compared to wild-type females
• 25% of mutants develop breast cancer before 1 year of age and 83% by 22 months of age
• 79% of tumors are positive for ERalpha and tumors are predominately luminal-like
• only 1 of 19 (5.3%) mammary tumors metastasize to the lung after 1 year of age

integument
• mammary glands of virgin females are enriched with luminal stem/progenitors at 6 weeks and 9 months of age compared to wild-type females
• 25% of mutants develop breast cancer before 1 year of age and 83% by 22 months of age
• 79% of tumors are positive for ERalpha and tumors are predominately luminal-like
• only 1 of 19 (5.3%) mammary tumors metastasize to the lung after 1 year of age

neoplasm
• 25% of mutants develop breast cancer before 1 year of age and 83% by 22 months of age
• 79% of tumors are positive for ERalpha and tumors are predominately luminal-like
• only 1 of 19 (5.3%) mammary tumors metastasize to the lung after 1 year of age




Genotype
MGI:2175774
hm3
Allelic
Composition
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
involves: 129/Sv * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• 10-month or older mice that develop a large pituitary adenoma appear thin
• become larger within 2-3 weeks of age
• body weight increases by 20%, 40%, and 30% at 1, 2, and 3 months of age, respectively
• disproportionately enlarged by 40%, 110%, and 90% at 1, 2, and 3 months of age, respectively
• exhibit increased cellularity in the spleen at 2 months of age

neoplasm
• develop intermediate lobe adenoma at 9 to 13 months of age

endocrine/exocrine glands
• disproportionate enlargement
• disproportionate and progressive enlargement
• age-dependent progression of pituitary gland hyperplasia, from mild intermediate lobe hyperplasia to moderate and severe hyperplasia, compression of adjacent lobes, and finally the development of intermediate lobe adenoma
• develop intermediate lobe adenoma at 9 to 13 months of age
• disproportionately enlarged; thymus weight is twice the body weight increase at 1 month, becomes proportionate to body weight increase at 2 months, and is disproportionately small at 3 months
• show a 40% increase in thymic cellularity
• although larger than wild-type testes, the testes of 1, 2, and 3 month old males are disproportionately small with respect to the body size

immune system
• disproportionately enlarged; thymus weight is twice the body weight increase at 1 month, becomes proportionate to body weight increase at 2 months, and is disproportionately small at 3 months
• show a 40% increase in thymic cellularity
• disproportionately enlarged by 40%, 110%, and 90% at 1, 2, and 3 months of age, respectively
• exhibit increased cellularity in the spleen at 2 months of age
• increased expansion of activated B cells
• display expansion of T lymphocytes
• T lymphocytes are hyper-responsive to mitogenic stimulation

behavior/neurological
• 10-month or older mice that develop a large pituitary adenoma are ataxic

homeostasis/metabolism
• 10-month or older mice that develop a large pituitary adenoma are dehydrated

reproductive system
• although larger than wild-type testes, the testes of 1, 2, and 3 month old males are disproportionately small with respect to the body size

hematopoietic system
• disproportionately enlarged; thymus weight is twice the body weight increase at 1 month, becomes proportionate to body weight increase at 2 months, and is disproportionately small at 3 months
• show a 40% increase in thymic cellularity
• disproportionately enlarged by 40%, 110%, and 90% at 1, 2, and 3 months of age, respectively
• exhibit increased cellularity in the spleen at 2 months of age
• show increased cellularity in the bone marrow at 2 months of age
• increased expansion of activated B cells
• display expansion of T lymphocytes
• T lymphocytes are hyper-responsive to mitogenic stimulation

nervous system
• disproportionate and progressive enlargement
• age-dependent progression of pituitary gland hyperplasia, from mild intermediate lobe hyperplasia to moderate and severe hyperplasia, compression of adjacent lobes, and finally the development of intermediate lobe adenoma
• develop intermediate lobe adenoma at 9 to 13 months of age




Genotype
MGI:5517370
cx4
Allelic
Composition
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Bhk mutation (0 available); any Brca1 mutation (114 available)
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mammary glands of virgin females show a decrease in the expansion of luminal progenitors seen in single Cdkn2c homozygotes to normal levels but show an increase in the expansion of basal/myoepithelial cells
• 38% of mutants develop breast cancer before 1 year of age and 87% by 22 months of age
• mammary tumors show high degree of heterogeneity, increased population of CK5+ cells, loss of wild-type allele of Brca1 in CK5+ tumor cells, ERalpha negativity and invasiveness and metastasis
• mammary tumors are transformed from a luminal subtype that is seen in single Cdkn2c homozygotes into a basal-like subtype
• poorly differentiated carcinoma with squamous metaplasia

integument
• mammary glands of virgin females show a decrease in the expansion of luminal progenitors seen in single Cdkn2c homozygotes to normal levels but show an increase in the expansion of basal/myoepithelial cells
• 38% of mutants develop breast cancer before 1 year of age and 87% by 22 months of age
• mammary tumors show high degree of heterogeneity, increased population of CK5+ cells, loss of wild-type allele of Brca1 in CK5+ tumor cells, ERalpha negativity and invasiveness and metastasis
• mammary tumors are transformed from a luminal subtype that is seen in single Cdkn2c homozygotes into a basal-like subtype
• poorly differentiated carcinoma with squamous metaplasia

neoplasm
• 38% of mutants develop breast cancer before 1 year of age and 87% by 22 months of age
• mammary tumors show high degree of heterogeneity, increased population of CK5+ cells, loss of wild-type allele of Brca1 in CK5+ tumor cells, ERalpha negativity and invasiveness and metastasis
• mammary tumors are transformed from a luminal subtype that is seen in single Cdkn2c homozygotes into a basal-like subtype
• poorly differentiated carcinoma with squamous metaplasia
• 4 of 13 (31%) mammary tumors metastasize to the lung and blood vessels after 1 year of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:198018




Genotype
MGI:5517367
cx5
Allelic
Composition
Brca1tm1Bhk/Brca1tm1Bhk
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Bhk mutation (0 available); any Brca1 mutation (114 available)
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• no viable embryos are identified beyond E14.5




Genotype
MGI:3639679
cx6
Allelic
Composition
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Genetic
Background
involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn1btm1Ako mutation (0 available); any Cdkn1b mutation (26 available)
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all die by 3.5 months of pituitary tumors

growth/size/body
• appear thin by 3 months of age

behavior/neurological
• appear ataxic by 3 months of age

homeostasis/metabolism
• appear dehydrated by 3 months of age

neoplasm
• develop pituitary tumors (by 3 months of age) at an accelerated rate compared to the single homozygous mice
• one mutant developed a pituitary carcinoma

cardiovascular system

endocrine/exocrine glands
• pituitary glands are larger than in single homozygous mutants
• develop pituitary tumors (by 3 months of age) at an accelerated rate compared to the single homozygous mice

hematopoietic system

reproductive system

nervous system
• pituitary glands are larger than in single homozygous mutants
• develop pituitary tumors (by 3 months of age) at an accelerated rate compared to the single homozygous mice

immune system




Genotype
MGI:3839785
cx7
Allelic
Composition
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+
Genetic
Background
involves: 129/Sv * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
Men1tm1.1Ctre mutation (2 available); any Men1 mutation (40 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• some mice exhibit Leydig cell adenocarcinomas
• some mice exhibit Leydig cell adenocarcinomas
• some mice exhibit Leydig cell adenocarcinomas
• most lung tumors are primary
• bronchioalveolar stem cells are expanded in lung tumors compared to in Cdkn2ctm1Yxi homozygotes or Men1tm1.1Ctre heterozygotes
• in 33% of mice before 1 year of age
• after 1 year of age, lung adenocarcinomas develop in 63% of mice including 3 carcinomas with neuroendocrine characteristics
• mice develop multiple lung carcinomas that are more aggressive and invasive than in single mutant mice
• neuroendocrine carcinomas are more proliferative and apoptotic than in single mutant mice
• tumors develop quicker than in Men1tm1.1Ctre heterozygotes

reproductive system
• some mice exhibit Leydig cell adenocarcinomas
• some mice exhibit Leydig cell adenocarcinomas

respiratory system
• most lung tumors are primary
• bronchioalveolar stem cells are expanded in lung tumors compared to in Cdkn2ctm1Yxi homozygotes or Men1tm1.1Ctre heterozygotes
• in 33% of mice before 1 year of age
• after 1 year of age, lung adenocarcinomas develop in 63% of mice including 3 carcinomas with neuroendocrine characteristics
• mice develop multiple lung carcinomas that are more aggressive and invasive than in single mutant mice
• neuroendocrine carcinomas are more proliferative and apoptotic than in single mutant mice

endocrine/exocrine glands
• some mice exhibit Leydig cell adenocarcinomas
• some mice exhibit Leydig cell adenocarcinomas




Genotype
MGI:3839786
cx8
Allelic
Composition
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1tm1.1Ctre
Genetic
Background
involves: 129/Sv * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2ctm1Yxi mutation (1 available); any Cdkn2c mutation (17 available)
Men1tm1.1Ctre mutation (2 available); any Men1 mutation (40 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• no viable double homozygous embryos were present beyond E15.5





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory